Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Mar / Logistical Nightmares
Manufacture Business Practice Small Molecules Trends & Forecasts Small Molecules

Logistical Nightmares

We’ve heard some of the shortcomings of pharma logistics, but what happens when things really go wrong?

By James Strachan 03/16/2018 1 min read

Share

Stan Wraight: The very first use of air cargo for biomedicals, and the atrocious incidents that occurred in their transportation, was a disaster. It came about because the airlines in the beginning were unaware of what was required, largely because of a lack of communication between airlines, shippers and consignees. Millions of dollars were lost, and one can only imagine the number of potential lives that were lost as a result of those medicines not reaching patients.

Mark Edwards: I’ve personally seen 36 pallets left on the tarmac at Dubai for two days. Not only was the stock financially valuable, it was also essential; the life-changing drugs were heading to a country where supplies were almost exhausted. The product had to be destroyed because of the effects of +50°C temperatures. Jan Krems: In terms of impact to the cargo industry and its customers, the biggest logistics disaster was the 2016 bankruptcy of the ocean container shipping line, Hanjin. There were hundreds of thousands of shipments delayed around the world – but worse than delayed, many were stuck on ships for months and neither the shippers nor consignees could get them. The value of the pharma stock that was stranded at sea was enormous. On a brighter note, last year we managed to mitigate a logistics disaster that could have been much worse: the impact of the hurricanes in Puerto Rico. The airports on the island began to open for arrival of flights of relief supplies and workers while the sea ports were still closed. Specifically, United was able to transport more than 1.7 million pounds of generators and other hurricane relief supplies to impacted areas of Puerto Rico and Texas. Because of United TempControl’s presence and operations in San Juan, our experts were able to meet with nearly every major pharma manufacturer on the island to discuss how to alleviate the crisis. Further disaster: In 1996, Foxmeyer Drug – then the second largest drug distributor in the US – tried to revamp its IT systems and its distribution facilities. Its new ERP system couldn’t cope with the volumes, and the highly automated distribution center (DC) in Ohio was riddled with bugs. According to Supply Chain Digest, “An order would be partially shipped due to DC problems. The customer would receive a partial order, and call to complain. Unable to see the rest of the order had shipped on a later truck, the customer service rep would authorize a replacement shipment for a product already on its way to the customer. Tens of millions of dollars in unrecoverable shipping errors ensued.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.